1. Home
  2. NWGL vs GANX Comparison

NWGL vs GANX Comparison

Compare NWGL & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nature Wood Group Limited

NWGL

Nature Wood Group Limited

HOLD

Current Price

$0.77

Market Cap

19.6M

Sector

N/A

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.96

Market Cap

72.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NWGL
GANX
Founded
2008
2017
Country
Macau
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.6M
72.7M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
NWGL
GANX
Price
$0.77
$1.96
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.20
AVG Volume (30 Days)
49.3K
756.5K
Earning Date
12-29-2025
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
47.95
EPS
N/A
N/A
Revenue
N/A
$55,180.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.65
$1.41
52 Week High
$6.61
$4.34

Technical Indicators

Market Signals
Indicator
NWGL
GANX
Relative Strength Index (RSI) 23.99 41.74
Support Level N/A $1.60
Resistance Level $1.47 $2.03
Average True Range (ATR) 0.12 0.21
MACD -0.05 -0.09
Stochastic Oscillator 20.83 14.90

Price Performance

Historical Comparison
NWGL
GANX

About NWGL Nature Wood Group Limited

CL Workshop Group Ltd, formerly Nature Wood Group Ltd is a vertically-integrated forestry company that focuses on FSC business operations. It produces various products, including logs, decking, flooring, sawn timber, recycled charcoal, synthesized charcoal, machine-made charcoal, and essential oils. The Group owns natural forest concessions and cutting rights for exploiting timbers on parcels of land in Peru. The Group is organized into two operating divisions; Direct Purchase and Original Design Manufacturer (ODM) Services, and Manufacturing segments. The Direct Purchase and ODM Segment that derives the majority of revenue engages in the business of sourcing live wood and owning designed designs on wood products for sales to end customers.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: